Gaining better perception into the affected person journey from prognosis by remedy is a precedence for drug builders as they search to provide more practical medicine. Utilizing non-small cell lung most cancers (NSCLC) for example, PurpleLab and Genentech will discover find out how to leverage actual world knowledge (RWD) to remove blind spots within the affected person journey — informing each part of a drug’s lifecycle, from medical growth to market entry.
The webinar will embody Purple Lab executives Russ Cobb, chief advertising and marketing officer and the webinar moderator, and Steve Emrick, senior vice chairman of medical informatics options and well being nexus. Additionally collaborating within the webinar is Dr. Ben Freiberg, Principal Informatics Techniques Lead with Genentech’s gCS Computational Catalysts. Genentech is owned by Roche.
A few of the speaking factors of the webinar embody:
- How can RWD be leveraged by pharma firms for the NSCLC affected person journey?
- What does the “typical” affected person journey for NSCLC appear like?
- Mapping the nuanced components of a affected person’s journey
- The worth of leveraging Social Determinants of Well being knowledge
- Addressing socioeconomic obstacles that will hinder medical trial participation
- Utilizing RWD to enhance medical trial recruitment, medical endpoints, and inform market entry methods
To register for the webinar sponsored by PurpleLab, Eliminating Blind Spots within the Affected person Journey, scheduled for 1-2 pm ET on Might 22, please fill out the shape beneath:
Picture: metamorworks, Getty Photographs
